Patients <18 years N (%) Patients ≥ 18 years N (%) Total patients N (%)
First intake of grass AIT 797 964 1,761
Follow-up information available 711 (89.2) 801 (83.1) 1,512 (85.9)
At least 1 Follow-up visit 693 (87.0) 784 (81.3) 1,477 (83.9)
Seasonal or post-seasonal visit 652 (81.8) 729 (75.6) 1,381 (78.4)
Premature study termination due to      
Adverse events 72 (9.0) 71 (7.4) 143 (8.1)
Contraindication, intercurrent disease 4 (0.5) 2 (0.2) 6 (0.3)
Pregnancy, wish to have a child - 8 (0.8) 8 (0.5)
Wish of patient / parents; patient refused administration 19 (2.4) 8 (0.8) 27 (1.5)
Change-over to another drug 8 (1.0) 13 (1.3) 21 (1.2)
Other reasons 7 (0.9) 21 (2.2) 28 (1.6)
Lacking compliance 76 (9.5) 171 (17.7) 247 (14.0)
Unknown (no information available) 45 (5.6) 86 (8.9) 131 (7.4)
Treatment continued after end of study 566 (71.0) 584 (60.6) 1,150 (65.3)
Table 2: Flow of patients through the study for pediatric patients (<18 years), adults (≥ 18 years) and total patients treated with the grass allergy immunotherapy tablet (AIT).
Goto home»